Please login to the form below
constipation
This page shows the latest constipation news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s weight-loss drug recommended by NICE
In terms of safety, patients reported the main side effects were gastrointestinal disorders including nausea, diarrhoea, constipation and vomiting.
Latest news
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
out of 18 HRQoL and disease-related symptoms scores, as well as better HRQoL and disease-related symptoms scores for physical functioning, fatigue, dyspnea and constipation versus Sutent.
-
Karuna’s shares spike on schizophrenia drug data
dose. The most common side effects were constipation, nausea, dry mouth, dyspepsia and vomiting.
-
Ardelyx gets second kidney disease trial win for tenapanor
Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review
-
China approves Ironwood Pharma’s IBS treatment
Approval by China’s NMPA for adults with irritable bowel syndrome with constipation (IBS-C) opens up the country's huge market to the treatment. ... This approval is incredibly important as it brings a new option to treat some of the bothersome
-
Shire bags US approval for constipation drug Motegrity
Approval is boost as Takeda takeover nears completion. Shire has the US approval it needs for Motegrity, a drug for chronic idiopathic constipation (CIC) that will compete with drugs like
More from news
Approximately 8 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
Case study: What we're made of
If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease.
-
Erectile dysfunction, constipation, vaginal dryness and other laughing matters
Diarrhoea, constipation, flatulence, leaky bladder, vaginal dryness - it’s all fertile territory.
-
Taking a lean and careful approach
His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation.
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
irritable bowel syndrome and constipation.
-
Norgine’s Karen Hockey promoted to head of global marketing
Appointment follows nearly two years as global brand manager for constipation treatment Movicol. ... Hockey's promotion comes after nearly two years as global brand manager for constipation treatment Movicol since joining Norgine in 2011.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
